Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery, Oncotarget, vol.6, pp.5501-5516, 2015. ,
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma, Oncotarget, vol.4, pp.2080-2095, 2013. ,
Bromodomains as therapeutic targets, Expert Rev. Mol. Med, vol.13, 2011. ,
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia, Nature, vol.478, pp.529-533, 2011. ,
Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A), Bioorg. Med. Chem. Lett, vol.22, pp.2968-2972, 2012. ,
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer, Oncotarget, vol.4, pp.2419-2429, 2013. ,
Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL, Oncotarget, vol.5, pp.3168-3172, 2014. ,
JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer, Oncotarget, vol.6, pp.6915-6930, 2015. ,
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma, Oncotarget, vol.6, pp.18921-18932, 2015. ,
Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling, Oncotarget, vol.6, pp.21507-21521, 2015. ,
BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells, Oncotarget, vol.6, pp.33397-33409, 2015. ,
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells, Oncotarget, vol.6, pp.33623-33635, 2015. ,
Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression, Oncotarget, vol.7, pp.2462-2474, 2016. ,
Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma, Oncotarget, vol.7, pp.1451-1463, 2016. ,
Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1, Oncotarget, vol.7, pp.24125-24140, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01702273
BET inhibition as a new strategy for the treatment of gastric cancer, Oncotarget, vol.7, pp.43997-44012, 2016. ,
Small-Molecule Targeting of BET Proteins in Cancer, Adv. Cancer Res, vol.131, pp.21-58, 2016. ,
Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond, Can. J. Cardiol, vol.32, pp.863-870, 2016. ,
ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), Eur. Heart J, vol.37, pp.2768-2801, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01788726
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate, Nat. Med, vol.12, pp.908-916, 2006. ,
Ultrastructural features of apoptosis, Scanning Microsc, vol.8, pp.653-665, 1994. ,
BET acetyl-lysine binding proteins control pathological cardiac hypertrophy, J. Mol. Cell. Cardiol, vol.63, pp.175-179, 2013. ,
BET bromodomains mediate transcriptional pause release in heart failure, Cell, vol.154, pp.569-582, 2013. ,
BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure, Sci. Transl. Med, vol.9, 2017. ,
BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-?B pathway, Exp Ther. Med, vol.10, pp.2319-2324, 2015. ,
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4, ACS Chem. Biol, vol.10, pp.1770-1777, 2015. ,
Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion, Oncotarget, vol.6, pp.15857-15870, 2015. ,
Therapeutic targeting of Myc-reprogrammed cancer cell metabolism, Cold Spring Harb. Symp. Quant. Biol, vol.76, pp.369-374, 2011. ,
Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis, Mol. Cell. Biol, vol.25, pp.6225-6234, 2005. ,
, Int. J. Mol. Sci, vol.20, p.1527, 2019.
Mitochondrial structure, function and dynamics are temporally controlled by c-Myc, PLoS ONE, vol.7, 2012. ,
Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition, Cell Rep, vol.8, pp.1919-1929, 2014. ,
Sex differences in anthracycline cardiotoxicity, Ital. J. Gend. -Specif. Med, vol.2, pp.47-54, 2016. ,
Sexual dimorphism of doxorubicin-mediated cardiotoxicity: Potential role of energy metabolism remodeling, Circ. Heart Fail, vol.8, pp.98-108, 2015. ,
Mitochondria: A central target for sex differences in pathologies, Clin. Sci, vol.131, pp.803-822, 2017. ,
Transition Metal Toxicity, p.206, 2013. ,
The importance of the gastrointestinal system in the pathogenesis of heart failure, Eur. Heart J, vol.26, pp.2368-2374, 2005. ,
Gut-Lung Connection in Pulmonary Arterial Hypertension, Am. J. Respir. Cell Mol. Biol, vol.56, pp.402-405, 2017. ,
The age factor for mitoxantrone's cardiotoxicity: Multiple doses render the adult mouse heart more susceptible to injury, Toxicology, vol.329, pp.106-119, 2015. ,
BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice, Blood, vol.125, pp.2724-2728, 2015. ,
Targeting BET bromodomains for cancer treatment, Epigenomics, vol.7, pp.487-501, 2015. ,
Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells, Nat. Protoc, vol.3, pp.965-976, 2008. ,
Cytochrome oxidase from beef heart mitochondria, Methods Enzymol, vol.10, pp.245-250, 1967. ,